Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.2%

1 terminated out of 24 trials

Success Rate

93.8%

+7.2% vs benchmark

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

33%

5 of 15 completed with results

Key Signals

5 with results94% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (10)
P 2 (2)
P 3 (3)

Trial Status

Completed15
Not Yet Recruiting4
Unknown2
Recruiting2
Terminated1

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT07430410Not ApplicableNot Yet Recruiting

Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test

NCT07190131Completed

Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test

NCT07308158Completed

Covid Flu A/B and RSV 4 in 1 Diagnostic Test

NCT07314905Phase 3Not Yet Recruiting

Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)

NCT07217639Not ApplicableNot Yet Recruiting

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings

NCT06734741Completed

Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use

NCT06191393Not ApplicableCompleted

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

NCT05728970Completed

Performance Evaluation of the LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B Tests at Point of Care (POC) Sites

NCT06800950Phase 3Not Yet Recruiting

Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

NCT06672692Not ApplicableRecruiting

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

NCT06229444Not ApplicableCompleted

Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI

NCT06207929Completed

Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections

NCT05732610Not ApplicableCompleted

MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study

NCT06127108Not ApplicableCompleted

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel

NCT06254820Phase 2RecruitingPrimary

Dose, Safety, and Pathogenicity of a New Influenza B Strain

NCT06175611Unknown

Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory Infection

NCT05787444Unknown

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)

NCT04810949Not ApplicableTerminated

Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml

NCT02287467Phase 3Completed

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

NCT01052480Phase 2Completed

Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

Scroll to load more

Research Network

Activity Timeline